Study of anti-Toxoplasma gondii effect of mPEG–PCL copolymeric loaded with pyrimethamine, in vitro

被引：0

作者：

Mobina Gholami ^{[1
]}

Hossein Danafer ^{[1
]}

Mitra Sadeghi ^{[2
]}

Ahmad Daryani ^{[3
]}

Seyed Abdollah Hosseini ^{[4
]}

Shirzad Gholami ^{[4
]}

机构：

[1] Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of Medical Sciences, Zanjan

[2] Department of Medicinal Chemistry, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan

[3] Student Research Committee, Mazandaran University of Medical Sciences, Sari

[4] Toxoplasmosis Research Center, Communicable Disease Institute, Mazandaran University of Medical Sciences, Mazandaran, Sari

[5] Department of Parasitology and Mycology, School of Medicine, Mazandaran University of Medical Science, 18 Km of Khazar Abad Road, Sari

来源：

AMB Express | / 15卷 / 1期

关键词：

Antiparasitic effect; In vitro; mPEG–PCL copolymer nanoparticles; Pyrimethamine; Toxoplasma gondii;

D O I：

10.1186/s13568-025-01876-8

中图分类号：

学科分类号：

摘要：

The discovery of new drugs with minimal toxicity is crucially important in the search for effective treatments for toxoplasmosis. The study aimed to assess the effectiveness of pyrimethamine-loaded mPEG–PCL copolymeric nanoparticles (mPEG–PCL–Pyr) against Toxoplasma gondii (T. gondii) tachyzoites. The nanoparticles were fabricated using a nano-precipitation method and characterized using DLS and AFM. Through MTT assay, the anti-toxoplasmic activity was gauged. Healthy and infected cell viability, infection index, proliferation index, plaque count, and size were evaluated. Results indicated a maximum drug loading capacity of 11.23% in the nanoparticles. Toxicity testing on Vero cells infected with tachyzoites revealed notable cytotoxic effects at pyrimethamine-equivalent concentrations of 20 and 40 mg/mL in the mPEG–PCL copolymeric nanoparticle formulation. However, as the results indicated, the administration of mPEG–PCL–Pyr resulted in the reduction of intracellular proliferation, infection index, and the number and size of plaques in comparison to uninfected treated cells (P < 0.05). The synthesized Nano drug exhibited slightly better performance than pyrimethamine, despite the lack of statistical significance in the observed distinction (p > 0.05). The study demonstrated that mPEG–PCL copolymeric nanoparticles containing pyrimethamine effectively impede the in vitro replication of T. gondii. The study demonstrated that mPEG–PCL copolymeric nanoparticles containing pyrimethamine effectively impede the in vitro replication of T. gondii. The impact of pyrimethamine resembled that of the synthesized nano-drug on T. gondii tachyzoites, suggesting the potential of these nanoparticles as a promising avenue for toxoplasmosis treatment. © The Author(s) 2025.

引用

共 47 条

[1] Alajmi R.A.A.-M.W., Metwally D., Al-Subaie H., Altamrah N., Barakat A.M., Abdel Moneim A.E., Al-Otaibi T.T., El-Khadragy M., Anti-Toxoplasma activity of silver nanoparticles green synthesized with Phoenix dactylifera and Ziziphus spina-christi extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice, Biosci Rep, (2019)
[2] Alday P.-H., Doggett J.-S., Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des Devel Ther, pp. 273-293, (2017)
[3] Antczak M., Dzitko K., Dlugonska H., Human toxoplasmosis–searching for novel chemotherapeutics, Biomed Pharmacother, 82, pp. 677-684, (2016)
[4] Arafa F.M., Said H., Osman D., Rezki N., Aouad M.R., Hagar M., Osman M., Elwakil B.H., Jaremko M., Tolba M.M., Nanoformulation-based 1, 2, 3-triazole sulfonamides for anti-toxoplasma in vitro study, Trop Med Infect Dis, 8, (2023)
[5] Assolini J.P., Concato V.M., Goncalves M.D., Carloto A.-C.-M., Conchon-Costa I., Pavanelli W.-R., Melanda F.-N., Costa I.-N., Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications, Parasitol Res, 116, pp. 1603-1615, (2017)
[6] Attias M., Teixeira D.E., Benchimol M., Vommaro R.C., Crepaldi P.H., De Souza W., The life-cycle of Toxoplasma gondii reviewed using animations, Parasit Vectors, 13, pp. 1-13, (2020)
[7] Awashra M., Mlynarz P., The toxicity of nanoparticles and their interaction with cells: an in vitro metabolomic perspective, Nanoscale Adv, 5, pp. 2674-2723, (2023)
[8] Barbosa B.F., Gomes A.O., Ferro E.A.V., Napolitano D.R., Mineo J.R., Silva N.M., Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models, Vet Parasitol, 187, pp. 44-52, (2012)
[9] Benavides J., Moreira-Rodriguez M., Jacobo-Velazquez D.A., Nanoformulations applied to the delivery of sulforaphane, Phytochemical nanodelivery systems as potential biopharmaceuticals, pp. 327-341, (2023)
[10] Chirgwin K., Hafner R., Leport C., Remington J., Andersen J., Bosler E.M., Roque C., Rajicic N., McAuliffe V., Morlat P., Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study, Clin Infect Dis, 34, 9, pp. 1243-1250, (2002)

← 1 2 3 4 5 →